GlassScriptPhysician profile
Fakhruddin Rakla
NPI 1932131505
$1,748.90
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $534 · 2021: $222 · 2022: $119 · 2023: $136 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.46 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $612.67 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $322.43 | 2019-2024 | Lokelma |
| Genentech USA, INC. | $119.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $116.68 | 2020 | |
| Philips North America LLC | $90.23 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $86.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.86 | 2019-2020 | |
| Insmed, INC. | $76.76 | 2019-2020 | |
| Inspire Medical Systems, INC. | $72.26 | 2023 | Inspire |
| Allergan, INC. | $56.41 | 2019-2020 | |
| Mylan Specialty L.P. | $37.59 | 2019-2021 | |
| Abbvie INC. | $22.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.91 | 2020 | |
| Shionogi INC | $13.20 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fakhruddin Rakla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.